<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01678456</url>
  </required_header>
  <id_info>
    <org_study_id>AFNET_A7</org_study_id>
    <nct_id>NCT01678456</nct_id>
  </id_info>
  <brief_title>Prospective Registration and Assessment of Serious Adverse Events Within the AFNET</brief_title>
  <acronym>AFNET A7</acronym>
  <official_title>Prospective Registration and Independent Assessment of Incidence, Clinical Relevance and Outcome of Serious Adverse Events (SAE) Registered in the German Competence Network on Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrial Fibrillation Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective registration and independent assessment of SAE associated with atrial&#xD;
      fibrillation such as thromboembolic events, and other cardiac and noncardiac complications by&#xD;
      a Critical Event Committee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF), the most common sustained rhythm disturbance, is associated with a&#xD;
      significantly enhanced mortality and morbidity due to thromboembolic events, and other&#xD;
      cardiac and noncardiac complications. Therefore the &quot;Network of Competence on Atrial&#xD;
      Fibrillation (AFNET)&quot; supported by the German Ministry for Education and Research (BMBF) was&#xD;
      established in order to collect clinical data on patients (pts) with AF (paroxysmal,&#xD;
      persistent, permanent) over a study period of 6 years with an expected sample size of 12,000&#xD;
      pts. Incidence, clinical relevance and outcome after SAE is recorded and assessed by a&#xD;
      Critical Event Committee (CEC).&#xD;
&#xD;
      The CEC-members (experts in cardiology and neurology) defined as SAE any death with or&#xD;
      without relationship to AF, cardio-embolic events (stroke, peripheral arterial embolism),&#xD;
      bleeding complications due to antithrombotic therapy, acute heart failure, syncope,&#xD;
      resuscitation; additionally, the complication of interventional strategies for AF-treatment&#xD;
      and other AF-independent SAEs.&#xD;
&#xD;
      Over a 3-year follow-up period, during 6-monthly and unscheduled visits, the SAEs are&#xD;
      systematically documented, blinded and their relationship to AF will be interpreted in detail&#xD;
      by the CEC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">13000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Assessment of Serious Advers Events</condition>
  <condition>Thromboembolic and Bleeding Complications</condition>
  <condition>Complications of Antiarrhythmic Drugs or Invasive Procedures</condition>
  <condition>Assessment by a Critical Event Committee</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Real-life population Patients with atrial fibrilation documented within the last 12 months&#xD;
        before enrollment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation documented by ECG not older then one year&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Oeff, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SAE-Zentrum Brandenburg/Havel Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Staedt. Klinikum, Department of Cardiology</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Critical Event Committee</keyword>
  <keyword>Serious adverse events</keyword>
  <keyword>Thromboembolic complications</keyword>
  <keyword>Cardiac and noncardiac complications</keyword>
  <keyword>Bleeding complications</keyword>
  <keyword>Acute heart failure</keyword>
  <keyword>Syncope</keyword>
  <keyword>Resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

